Ionis Pharmaceuticals Has Completed Enrollment In The Pivotal Trial Of Zilganersen (ION373) For The Treatment Of Children And Adults With A Rare, Progressive Neurological Disorder Known As Alexander Disease. Topline Data Are Anticipated In 2H Of 2025
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals has completed enrollment in the pivotal trial of Zilganersen (ION373) for treating Alexander Disease, a rare neurological disorder. Topline data are expected in the second half of 2025.
July 18, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ionis Pharmaceuticals has completed enrollment in the pivotal trial of Zilganersen (ION373) for Alexander Disease. Topline data are expected in the second half of 2025.
The completion of enrollment in a pivotal trial is a significant milestone for Ionis Pharmaceuticals. It indicates progress in their clinical development pipeline, which could positively impact investor sentiment. The anticipation of topline data in 2H 2025 provides a timeline for potential future developments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100